Objective. To provide preliminary data regarding the efficacy and tolerability of the omega-3 fatty acids (omega-3FA) docosahexaenoic acid (DMA) and eicosapentaenoic acid (EPA) in adolescents with major depression (MOD). Rationale. Evidence links central monoamine dysfunction, neurocellular alterations, and immune system dysregulation with MDD. Omega-3FA have been found to have powerful modulatory effects on central monoaminergic activity, are essential structural and functional components of neurons and glia, are effective anti-inflammatory agents, and may be effective in adult mood disorders. A body of epidemiological and neurobiological findings link omega-3FA and MDD. These related observations provide the basis for the proposed study. Hypothesis. Omega-3FA treatment is superior to placebo in adolescents with MDD. Methods. Subjects. 40 medically healthy, antidepressant na?ve adolescents, ages 12-18, with MDD for at least 8 weeks and a minimum severity score of >40 on the CDRS-R, and onset of first episode > 12 years. Diagnosis. MDD will be established with the K-SADS-PL. Excluded will be current and past: bipolar disorder, schizophrenia, psychosis, autism, pervasive developmental disorder, .and Tourette's disorder; current post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, conduct disorder, eating disorders, and substance related disorders. Study Treatments. Adolescents will be randomized to 10 weeks of double blind treatment with omega3-FA or matching placebo. Dose will be initiated at 1.2mg/d, titrated flexibly every 2 weeks up to a maximum of 3.6g/d. Omega3-FA will be combined EPA/DHA (ratio 2:1). A minimum of two weeks' duration at lower doses will provide the opportunity to assess clinical response at any one dose. Subjects will be followed weekly by a child psychiatrist. Assessments will include determination of MDD (K-SADS), MDD severity (Children's Depression Rating Scale-Revised [CDRS-R]), clinical global improvement (CGI), adverse events/vital signs, suicidal ideation, food intake checklist. Data Analyses. Two primary outcomes will be used to test the hypothesis: MDD severity indexed by CDRS total scores, and a CGI rating of 1 or 2 (Very Much or Much Improved). An intent to treat design will be applied, controlling for background food intake and other pertinent covariates, if appropriate. Significance. Adolescent MDD is associated with serious functional impairments, including suicide, and represents a major public health concern. In spite of its importance, it has been subject to relatively little biological research. This study stands at the confluence of current efforts to improve the treatment of adolescents with MDD and to develop alternative therapeutic approaches for this group. Should results of this pilot study suggest efficacy and tolerability of omega-3FA, we will plan a larger study to provide an adequate test of omega-3FA efficacy in this clinical population.

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AT002395-01A2
Application #
7031950
Study Section
Special Emphasis Panel (ZAT1-JH (11))
Program Officer
Stoney, Catherine
Project Start
2005-09-30
Project End
2008-08-31
Budget Start
2005-09-30
Budget End
2006-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$253,500
Indirect Cost
Name
New York University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Henderson, Sarah E; Vallejo, Ana I; Ely, Benjamin A et al. (2014) The neural correlates of emotional face-processing in adolescent depression: a dimensional approach focusing on anhedonia and illness severity. Psychiatry Res 224:234-41
Gabbay, Vilma; Ely, Benjamin A; Li, Qingyang et al. (2013) Striatum-based circuitry of adolescent depression and anhedonia. J Am Acad Child Adolesc Psychiatry 52:628-41.e13
Gabbay, Vilma; Mao, Xiangling; Klein, Rachel G et al. (2012) Anterior cingulate cortex ?-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry 69:139-49
Gabbay, Vilma; Ely, Benjamin A; Babb, James et al. (2012) The possible role of the kynurenine pathway in anhedonia in adolescents. J Neural Transm (Vienna) 119:253-60
Gabbay, Vilma; Babb, James S; Klein, Rachel G et al. (2012) A double-blind, placebo-controlled trial of ?-3 fatty acids in Tourette's disorder. Pediatrics 129:e1493-500
Gabbay, Vilma; Klein, Rachel G; Katz, Yisrael et al. (2010) The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 51:935-43
Gabbay, Vilma; Liebes, Leonard; Katz, Yisrael et al. (2010) The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 34:37-44
Gabbay, Vilma; Klein, Rachel G; Guttman, Leah E et al. (2009) A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol 19:423-30
Gabbay, Vilma; Klein, Rachel G; Alonso, Carmen M et al. (2009) Immune system dysregulation in adolescent major depressive disorder. J Affect Disord 115:177-82
Gabbay, Vilma; Coffey, Barbara J; Guttman, Leah E et al. (2009) A cytokine study in children and adolescents with Tourette's disorder. Prog Neuropsychopharmacol Biol Psychiatry 33:967-71

Showing the most recent 10 out of 12 publications